Triple negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer (BC) for which limited therapeutic options are available.

Recently, β-blockers (BBs) have been suggested to have favorable effects in the treatment of BC. The REpurposing Drugs in Oncology (ReDO) project investigated the potential use of off patent non-cancer drugs as sources of new potentially cheaper, effective, and safe drugs.

In line with this project, this systematic review was performed to collect evidence from preclinical and clinical studies concerning the scientific evidence for the repurposing of BBs in TNBC treatment.

Read the full article here.